Allen R H, Seetharam B, Allen N C, Podell E R, Alpers D H
J Clin Invest. 1978 Jun;61(6):1628-34. doi: 10.1172/JCI109083.
In vitro studies indicate that [(57)Co]cobalamin (Cbl) is preferentially bound to salivary R protein as opposed to intrinsic factor (IF) and that [(57)Co]Cbl bound to R protein is not transferred to IF at either pH 2 or pH 8. Incubation of R protein-[(57)Co]Cbl with pancreatic proteases causes a partial degradation of the R protein moiety and a rapid transfer of [(57)Co]Cbl to IF. We have postulated that the etiology of Cbl malabsorption in pancreatic insufficiency is an inability to partially degrade R protein because of a lack of pancreatic proteases. We have tested this hypothesis by determining the ability of a nonradioactive Cbl analogue, bound with high affinity by R protein but not by IF, to correct the malabsorption of [(57)Co]Cbl in patients with pancreatic insufficiency.R protein bound the Cbl analogue known as cobinamide with affinities that were the same and only 14-fold lower than those for Cbl at pH 8 and pH 2, respectively. Cobinamide was bound by IF with affinities that were 600,000- and 10,000-fold lower than those for Cbl at pH 8 and 2, respectively. The addition of 125 pmol of nonradioactive cobinamide to 0.5 pmol of [(57)Co]Cbl before being added to 1 pmol of R protein and 1 pmol of IF, markedly inhibited the ability of R protein to compete with IF for binding the [(57)Co]Cbl. Similar results were obtained with freshly aspirated gastric juice. This change was essentially indistinguishable from that observed previously when R protein or R protein-[(57)Co]Cbl was incubated in vitro with trypsin. The oral administration of 100 nmol of nonradioactive cobinamide in Schilling tests was equivalent to trypsin in its ability to completely correct the malabsorption of 0.4 nmol of [(57)Co]Cbl in three patients with pancreatic insufficiency. The fact that both trypsin and nonradioactive cobinamide inhibit the ability of R protein to compete with IF for [(57)Co]Cbl binding in vitro, and correct the mal-absorption of [(57)Co]Cbl in patients with pancreatic insufficiency in vivo, supports our hypothesis that the primary defect in Cbl absorption in this disease is an inability to partially degrade R protein because of a lack of pancreatic proteases.
体外研究表明,[(57)钴]钴胺素(Cbl)优先与唾液R蛋白结合,而非内因子(IF),且与R蛋白结合的[(57)钴]Cbl在pH 2或pH 8时均不会转移至IF。将R蛋白-[(57)钴]Cbl与胰蛋白酶一起孵育会导致R蛋白部分降解,并使[(57)钴]Cbl迅速转移至IF。我们推测,胰腺功能不全时Cbl吸收不良的病因是由于缺乏胰蛋白酶而无法使R蛋白部分降解。我们通过测定一种非放射性Cbl类似物纠正胰腺功能不全患者[(57)钴]Cbl吸收不良的能力来检验这一假设,该类似物能被R蛋白高亲和力结合,但不能被IF结合。R蛋白与称为钴胺酰胺的Cbl类似物结合的亲和力在pH 8和pH 2时分别与Cbl相同,仅低14倍。钴胺酰胺与IF结合的亲和力在pH 8和pH 2时分别比Cbl低600,000倍和10,000倍。在将0.5 pmol的[(57)钴]Cbl加入1 pmol的R蛋白和1 pmol的IF之前,先加入125 pmol的非放射性钴胺酰胺,可显著抑制R蛋白与IF竞争结合[(57)钴]Cbl的能力。新鲜抽取的胃液也得到了类似结果。这种变化与之前在体外将R蛋白或R蛋白-[(57)钴]Cbl与胰蛋白酶孵育时观察到的变化基本无法区分。在希林试验中口服100 nmol的非放射性钴胺酰胺,在完全纠正三名胰腺功能不全患者0.4 nmol [(57)钴]Cbl吸收不良方面,其能力与胰蛋白酶相当。胰蛋白酶和非放射性钴胺酰胺在体外均能抑制R蛋白与IF竞争结合[(57)钴]Cbl的能力,且在体内均能纠正胰腺功能不全患者[(57)钴]Cbl的吸收不良,这一事实支持了我们的假设,即该疾病中Cbl吸收的主要缺陷是由于缺乏胰蛋白酶而无法使R蛋白部分降解。